Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) – Pipeline Review, H2 2017’, provides an overview of the Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)

The report reviews pipeline therapeutics for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) therapeutics and enlists all their major and minor projects

The report assesses Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AstraZeneca Plc

Blueprint Medicines Corp

Clementia Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

La Jolla Pharmaceutical Company

Oncodesign SA

Pfizer Inc

Regeneron Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Overview

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Companies Involved in Therapeutics Development

AstraZeneca Plc

Blueprint Medicines Corp

Clementia Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

La Jolla Pharmaceutical Company

Oncodesign SA

Pfizer Inc

Regeneron Pharmaceuticals Inc

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Drug Profiles

Antibody to Antagonize ALK2 for Fibrodysplasia Ossificans Progressiva Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLU-782 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dipyridamole Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Fibrodysplasia Ossificans Progressiva Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJPC-6417 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palovarotene Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-2477 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-2477 + trevogrumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

saracatinib difumarate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sirolimus Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Activin Receptor-Like Kinase 2 for fibrodysplasia ossificans progressiva Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Dormant Projects

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Product Development Milestones

Featured News & Press Releases

Dec 12, 2017: Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva

Aug 31, 2017: Clementia Announces Data Presentations at Upcoming Medical Conferences in September

Jun 05, 2017: Clementia Pharmaceuticals to Host Symposium at the 8th International Conference on Children’s Bone Health

Mar 28, 2017: Phase 2 Part A Open Label Extension Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva Continues Positive Trends

Oct 14, 2016: Clementia Announces Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva

Aug 08, 2016: Clementia Clinical Program: Opportunity for New Adult and Older Adolescent Subjects to Enroll in Palovarotene Study

Jun 13, 2016: Clementia Clinical Program: Next Step in Clementia’s Clinical Program for Fibrodysplasia Ossificans Progressiva (FOP)

Apr 23, 2016: Clementia Pharmaceuticals Joins Global FOP Community in Recognizing Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Pipeline by AstraZeneca Plc, H2 2017

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Pipeline by Blueprint Medicines Corp, H2 2017

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Pipeline by Clementia Pharmaceuticals Inc, H2 2017

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Pipeline by La Jolla Pharmaceutical Company, H2 2017

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Pipeline by Oncodesign SA, H2 2017

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Pipeline by Pfizer Inc, H2 2017

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Pipeline by Regeneron Pharmaceuticals Inc, H2 2017

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Dormant Projects, H2 2017

List of Figures

List of Figures

Number of Products under Development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports